---
title: "Wegovy (semaglutide) in chronic weight management: Indication questions"
description: "Indication questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Wegovy approved for in weight management? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Indication questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Indication questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications: Indication](https://www.evicenter.com/medical-information/wegovy/indication).

## Indication

<a id="wegovy-indication"></a>

### What is Wegovy approved for in weight management?

> “WEGOVY<sup>®</sup> injection is indicated in combination with a reduced 
> calorie diet and increased physical activity:”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “•	To reduce excess body weight and maintain weight reduction 
> long term in:
> 	 •	Adults and pediatric patients aged 12 years and older with 
> obesity.
>  	 •	Adults with overweight in the presence of at least one 
> weight-related comorbid condition.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “WEGOVY<sup>®</sup> tablets are indicated in combination with a reduced 
> calorie diet and increased physical activity:”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “•	To reduce excess body weight and maintain weight reduction 
> long term in adults with obesity, or in adults with overweight 
> in the presence of at least one weight-related comorbid 
> condition.”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

Note: The label also lists reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (injection and tablets) and noncirrhotic MASH with moderate to advanced liver fibrosis in adults (injection) as separate indications.

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Clinical trials](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage)
